Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases

Frontiers in Bioscience

Volumn 14, Issue 5, 2009, Pages 1793-1806

  Westman Brinkmalm, Ann ^a   Ruetschi, Ulla ^a   Portelius, Erik ^a   Andreasson, Ulf ^a   Brinkmalm, Gunnar ^a   Karlsson, Gosta ^a   Hansson, Sara ^a   Zetterberg, Henrik ^a   Blennow, Kaj ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; Cerebrospinal fluid; Frontotemporal dementia; Multiple sclerosis; Proteomics; Review

Indexed keywords

BIOLOGICAL MARKER; PEPTIDE;

CEREBROSPINAL FLUID; DEGENERATIVE DISEASE; HUMAN; MASS SPECTROMETRY; METABOLISM; METHODOLOGY; PROTEOMICS; REVIEW; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BIOLOGICAL MARKERS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MASS SPECTROMETRY; NEURODEGENERATIVE DISEASES; PEPTIDES; PROTEOMICS;

EID: 63849165806     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3341     Document Type: Review

References (85)

1. C.L. Nilsson, G. Karlsson, J. Bergquist, A. Westman, and R. Ekman: Mass Spectrometry of Peptides in Neuroscience. Peptides, 19, 781-789 (1998). (Pubitemid 28255017)
2. L. Paulson; R. Persson, G. Karlsson, J. Silberring, A. Bierczynska-Krzysik, R. Ekman, and A. Westman-Brinkmalm: Proteomics and peptidomics in neuroscience. Experience of capabilities and limitations in a neurochemical laboratory. J Mass Spectrom. 40, 202-213 (2005). (Pubitemid 40327260)
3. S.F. Hansson, A.H. Simonsen, H. Zetterberg, O. Andersen, S. Haghighi, I. Fagerberg, U. Andreasson, A. Westman-Brinkmalm, A. Wallin, U. Ruetschi and K. Blennow: Cystatin C in cerebrospinal fluid and multiple sclerosis. Ann Neurol 62, 193-196 (2007). (Pubitemid 47546505)
4. N. Mattsson, U. Rüetschi, V.N. Podust, M. Stridsberg, S. Li, O. Andersen, S. Haghighi, K. Blennow and H. Zetterberg: Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J Neurochem In press, (2007).
5. U. Ruetschi, H. Zetterberg, V.N. Podust, J. Gottfries, S. Li, A. Hviid Simonsen, J. McGuire, M. Karlsson, L. Rymo, H. Davies, L. Minthon and K. Blennow: Identification of CSF biomarkers for frontotemporal dementia using SELDITOF. Exp Neurol 196, 273-281 (2005). (Pubitemid 41607815)
6. A.H. Simonsen, S.F. Hansson, U. Ruetschi, J. McGuire, V.N. Podust, H.A. Davies, P. Mehta, G. Waldemar, H. Zetterberg, N. Andreasen, A. Wallin and K. Blennow: Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods. Dement Geriatr Cogn Disord 23, 246-250 (2007). (Pubitemid 46496811)
7. A.H. Simonsen, J. McGuire, O. Hansson, H. Zetterberg, V.N. Podust, H.A. Davies, G. Waldemar, L. Minthon and K. Blennow: Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64, 366-370 (2007). (Pubitemid 46425690)
8. A.H. Simonsen, J. McGuire, V.N. Podust, H. Davies, L. Minthon, I. Skoog, N. Andreasen, A. Wallin, G. Waldemar and K. Blennow: Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging (2007).
9. P. Davidsson, M. Sjogren, N. Andreasen, M. Lindbjer, C.L. Nilsson, A. Westman-Brinkmalm and K. Blennow: Studies of the pathophysiological mechanisms in frontotemporal dementia by proteome analysis of CSF proteins. Brain Res Mol Brain Res 109, 128-133 (2002). (Pubitemid 36082878)
10. P. Davidsson, A. Westman-Brinkmalm, C.L. Nilsson, M. Lindbjer, L. Paulson, N. Andreasen, M. Sjogren and K. Blennow: Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 13, 611-615 (2002). (Pubitemid 34293477)
11. S.F. Hansson, M. Puchades, K. Blennow, M. Sjogren and P. Davidsson: Validation of a prefractionation method followed by two-dimensional electrophoresis - Applied to cerebrospinal fluid proteins from frontotemporal dementia patients. Proteome Sci 2, 7 (2004).
12. M. Puchades, S.F. Hansson, C.L. Nilsson, N. Andreasen, K. Blennow and P. Davidsson: Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 118, 140-146 (2003). (Pubitemid 37238996)
13. D. Ribom, A. Westman-Brinkmalm, A. Smits and P. Davidsson: Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas. Tumour Biol 24, 94-99 (2003). (Pubitemid 36829119)
14. E. Portelius, H. Zetterberg, U. Andreasson, G. Brinkmalm, N. Andreasen, A. Wallin, A. Westman-Brinkmalm and K. Blennow: An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. Neurosci Lett 409, 215-219 (2006). (Pubitemid 44648565)
15. K.K. Challapalli, C. Zabel, J. Schuchhardt, A.M. Kaindl, J. Klose and H. Herzel: High reproducibility of large-gel two-dimensional electrophoresis. Electrophoresis 25, 3040-3047 (2004). (Pubitemid 39294856)
16. T.W. Hutchens and T.T. Yip: New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 7, 576-580 (1993).
17. M. Merchant and S.R. Weinberger: Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21, 1164-1177 (2000). (Pubitemid 30230781)
18. S.R. Weinberger, E.A. Dalmasso and E.T. Fung: Current achievements using ProteinChip Array technology. Curr Opin Chem Biol 6, 86-91 (2002). (Pubitemid 34122041)
19. D. Beher, J.D. Wrigley, A.P. Owens and M.S. Shearman: Generation of C-terminally truncated amyloidbeta peptides is dependent on gamma-secretase activity. J Neurochem 82, 563-575 (2002). (Pubitemid 34835674)
20. C. Esh, L. Patton, W. Kalback, T.A. Kokjohn, J. Lopez, D. Brune, A.J. Newell, T. Beach, D. Schenk, D. Games, S. Paul, K. Bales, B. Ghetti, E.M. Castano and A.E. Roher: Altered APP processing in PDAPP (Val717 -> Phe) transgenic mice yields extended-length Abeta peptides. Biochemistry 44, 13807-13819 (2005). (Pubitemid 41507461)
21. E. Head, K. Moffat, P. Das, F. Sarsoza, W.W. Poon, G. Landsberg, C.W. Cotman and M.P. Murphy: Beta-amyloid deposition and tau phosphorylation in clinically characterized aged cats. Neurobiol Aging 26, 749-763 (2005). (Pubitemid 40228766)
22. P. Lewczuk, H. Esselmann, T.W. Groemer, M. Bibl, J.M. Maler, P. Steinacker, M. Otto, J. Kornhuber and J. Wiltfang: Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol Psychiatry 55, 524-530 (2004). (Pubitemid 38338541)
23. P. Lewczuk, H. Esselmann, M. Meyer, V. Wollscheid, M. Neumann, M. Otto, J.M. Maler, E. Ruther, J. Kornhuber and J. Wiltfang: The amyloid-beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun Mass Spectrom 17, 1291-1296 (2003). (Pubitemid 36750013)
24. H.D. Lewis, D. Beher, D. Smith, L. Hewson, N. Cookson, D.S. Reynolds, G.R. Dawson, M. Jiang, L.H. Van der Ploeg, S. Qian, T.W. Rosahl, R.N. Kalaria and M.S. Shearman: Novel aspects of accumulation dynamics and A beta composition in transgenic models of AD. Neurobiol Aging 25, 1175-1185 (2004). (Pubitemid 39094020)
25. A.S. Maddalena, A. Papassotiropoulos, C. Gonzalez-Agosti, A. Signorell, T. Hegi, T. Pasch, R.M. Nitsch and C. Hock: Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology. Neurodegener Dis 1, 231-235 (2004). (Pubitemid 39551802)
26. H. Davies, L. Lomas and B. Austen: Profiling of amyloid beta peptide variants using SELDI Protein Chip arrays. Biotechniques 27, 1258-1261 (1999).
27. J. Gobom, K.O. Kraeuter, R. Persson, H. Steen, P. Roepstorff, and R. Ekman: Detection and quantification of neurotensin in human brain tissue by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Chem. 72, 3320-3326 (2000). (Pubitemid 30482510)
28. E. Portelius, A.J. Tran, U. Andreasson, R. Persson, G. Brinkmalm, H. Zetterberg, K. Blennow and A. Westman-Brinkmalm: Characterization of Amyloid beta Peptides in Cerebrospinal Fluid by an Automated Immunoprecipitation Procedure Followed by Mass Spectrometry. J Proteome Res 6, 4433-4439 (2007). (Pubitemid 350158518)
29. E. Portelius, A. Westman-Brinkmalm, H. Zetterberg and K. Blennow: Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J Proteome Res 5, 1010-1016 (2006).
30. H. Reiber: Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310, 173-186 (2001). (Pubitemid 32728347)
31. O. Hansson, H. Zetterberg, P. Buchhave, E. Londos, K. Blennow and L. Minthon: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5, 228-234 (2006). (Pubitemid 43238346)
32. H. Zetterberg, L.O. Wahlund and K. Blennow: Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 352, 67-69 (2003). (Pubitemid 37412328)
33. M.C. Irizarry: Biomarkers of Alzheimer disease in plasma. NeuroRx 1, 226-234 (2004). (Pubitemid 46591884)
34. A. Westman, C.L. Nilsson and R. Ekman: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis of proteins in human cerebrospinal fluid. Rapid Commun Mass Spectrom 12, 1092-1098 (1998). (Pubitemid 28370227)
35. N. Andreasen, L. Minthon, P. Davidsson, E. Vanmechelen, H. Vanderstichele, B. Winblad and K. Blennow: Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 58, 373-379 (2001). (Pubitemid 32217453)
36. K. Blennow, A. Wallin and O. Hager: Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol Scand 88, 221-223. (1993). (Pubitemid 23288659)
37. E.R. Peskind, R. Riekse, J.F. Quinn, J. Kaye, C.M. Clark, M.R. Farlow, C. Decarli, C. Chabal, D. Vavrek, M.A. Raskind and D. Galasko: Safety and acceptability of the research lumbar puncture. Alzheimer Dis Assoc Disord 19, 220-225 (2005). (Pubitemid 44366623)
38. L.A. Farrer, L.A. Cupples, J.L. Haines, B. Hyman, W.A. Kukull, R. Mayeux, R.H. Myers, M.A. Pericak-Vance, N. Risch and C.M. van Duijn: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. Jama 278, 1349-1356 (1997). (Pubitemid 27449696)
39. D.E. Schmechel, A.M. Saunders, W.J. Strittmatter, B.J. Crain, C.M. Hulette, S.H. Joo, M.A. Pericak-Vance, D. Goldgaber and A.D. Roses: Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset alzheimer disease. Proc Natl Acad Sci U S A 90, 9649-9653 (1993). (Pubitemid 23315843)
40. J.A. Prince, H. Zetterberg, N. Andreasen, J. Marcusson and K. Blennow: APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 62, 2116-2118 (2004). (Pubitemid 38738236)
41. C. Hesse, H. Larsson, P. Fredman, L. Minthon, N. Andreasen, P. Davidsson and K. Blennow: Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res 25, 511-517 (2000). (Pubitemid 30317684)
42. A.L. Schwarzman, L. Gregori, M.P. Vitek, S. Lyubski, W.J. Strittmatter, J.J. Enghilde, R. Bhasin, J. Silverman, K.H. Weisgraber, P.K. Coyle and et al.: Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A 91, 8368-8372 (1994). (Pubitemid 24273665)
43. L. Liu and R.M. Murphy: Kinetics of Inhibition of beta-Amyloid Aggregation by Transthyretin. Biochemistry 45, 15702-15709 (2006). (Pubitemid 46032490)
44. A.B. Goodman: Retinoid receptors, transporters, and metabolizers as therapeutic targets in late onset alzheimer disease. J Cell Physiol 209, 598-603 (2006). (Pubitemid 44665675)
45. G. Arroyave and M. Calcano: [Decrease in serum levels of retinol and its binding protein (RBP) in infection]. Arch Latinoam Nutr 29, 233-260 (1979). (Pubitemid 10235236)
46. S. Hoving, H. Voshol and J. van Oostrum: Towards high performance two-dimensional gel electrophoresis using ultrazoom gels. Electrophoresis 21, 2617-2621 (2000). (Pubitemid 30646296)
47. R. Wildgruber, A. Harder, C. Obermaier, G. Boguth, W. Weiss, S.J. Fey, P.M. Larsen and A. Gorg: Towards higher resolution: two-dimensional electrophoresis of Saccharomyces cerevisiae proteins using overlapping narrow immobilized pH gradients. Electrophoresis 21, 2610-2616 (2000). (Pubitemid 30646295)
48. J. Zhang, D.R. Goodlett, J.F. Quinn, E. Peskind, J.A. Kaye, Y. Zhou, C. Pan, E. Yi, J. Eng, Q. Wang, R.H. Aebersold and T.J. Montine: Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7, 125-133; discussion 173-180 (2005). (Pubitemid 40592186)
49. F. Abdi, J.F. Quinn, J. Jankovic, M. McIntosh, J.B. Leverenz, E. Peskind, R. Nixon, J. Nutt, K. Chung, C. Zabetian, A. Samii, M. Lin, S. Hattan, C. Pan, Y. Wang, J. Jin, D. Zhu, G.J. Li, Y. Liu, D. Waichunas, T.J. Montine and J. Zhang: Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9, 293-348 (2006). (Pubitemid 44253348)
50. Y. Hu, J.P. Malone, A.M. Fagan, R.R. Townsend and D.M. Holtzman: Comparative proteomic analysis of intra and interindividual variation in human cerebrospinal fluid. Mol Cell Proteomics 4, 2000-2009 (2005).
51. P. Davidsson, S. Folkesson, M. Christiansson, M. Lindbjer, B. Dellheden, K. Blennow and A. Westman-Brinkmalm: Identification of proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing as a prefractionation step followed by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun Mass Spectrom 16, 2083-2088 (2002). (Pubitemid 35340074)
52. O. Carrette, I. Demalte, A. Scherl, O. Yalkinoglu, G. Corthals, P. Burkhard, D.F. Hochstrasser and J.C. Sanchez: A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3, 1486-1494.
53. P.D. Mehta, T. Pirttila, S.P. Mehta, E.A. Sersen, P.S. Aisen and H.M. Wisniewski: Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57, 100-105 (2000). (Pubitemid 30027637)
54. N.S. Schoonenboom, C. Mulder, G.J. Van Kamp, S.P. Mehta, P. Scheltens, M.A. Blankenstein and P.D. Mehta: Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same? Ann Neurol 58, 139-142 (2005). (Pubitemid 40962469)
55. J. Rogers, N.R. Cooper, S. Webster, J. Schultz, P.L. McGeer, S.D. Styren, W.H. Civin, L. Brachova, B. Bradt, P. Ward and et al.: Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 89, 10016-10020 (1992).
56. M. Zetterberg, S. Landgren, M.E. Andersson, M.S. Palmer, D.R. Gustafson, I. Skoog, L. Minthon, D.S. Thelle, A. Wallin, N. Bogdanovic, N. Andreasen, K. Blennow and H. Zetterberg: Association of complement factor H Y402H gene polymorphism with Alzheimer□s disease. American Journal of Medical Genetics, in press (2007).
57. K. Blennow, P. Davidsson, A. Wallin, C.G. Gottfries and L. Svennerholm: Ubiquitin in cerebrospinal fluid in Alzheimer's disease and vascular dementia. Int Psychogeriatr 6, 13-22; discussion 59-60 (1994).
58. G.P. Wang, K. Iqbal, G. Bucht, B. Winblad, H.M. Wisniewski and I. Grundke-Iqbal: Alzheimer's disease: paired helical filament immunoreactivity in cerebrospinal fluid. Acta Neuropathol (Berl) 82, 6-12 (1991).
59. K.K. Chung, V.L. Dawson and T.M. Dawson: The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci 24, S7-14 (2001).
60. D. Galasko and K. Marder: Picking away at frontotemporal dementia. Neurology 58, 1585-1586 (2002). (Pubitemid 34602884)
61. H. Arai, Y. Morikawa, M. Higuchi, T. Matsui, C.M. Clark, M. Miura, N. Machida, V.M.Y. Lee, J.Q. Trojanowski and H. Sasaki: Cerebrospinal Fluid Tau Levels in Neurodegenerative Diseases with Distinct Tau-Related Pathology. Biochemical and Biophysical Research Communications 236, 262-264 (1997). (Pubitemid 27373280)
62. A.J. Green, R.J. Harvey, E.J. Thompson and M.N. Rossor: Increased S100beta in the cerebrospinal fluid of patients with frontotemporal dementia. Neurosci Lett 235, 5-8 (1997). (Pubitemid 27471091)
63. A.J.E. Green, R.J. Harvey, E.J. Thompson and M.N. Rossor: Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease. Neuroscience Letters 259, 133-135 (1999). (Pubitemid 29064148)
64. H. Hampel and S.J. Teipel: Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia. Dement Geriatr Cogn Disord 17, 350-354 (2004). (Pubitemid 38721157)
65. M. Riemenschneider, S. Wagenpfeil, J. Diehl, N. Lautenschlager, T. Theml, B. Heldmann, A. Drzezga, T. Jahn, H. Forstl and A. Kurz: Tau and Abeta42 protein in CSF of patients with frontotemporal degeneration. Neurology 58, 1622-1628 (2002). (Pubitemid 34602892)
66. L.E. Rosengren, J.E. Karlsson, M. Sjogren, K. Blennow and A. Wallin: Neurofilament protein levels in CSF are increased in dementia. Neurology 52, 1090-1093 (1999). (Pubitemid 29161631)
67. M. Sjogren, L. Rosengren, L. Minthon, P. Davidsson, K. Blennow and A. Wallin: Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 54, 1960-1964 (2000). (Pubitemid 30327120)
68. B.D. Trapp, J. Peterson, R.M. Ransohoff, R. Rudick, S. Mork and L. Bo: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338, 278-285 (1998). (Pubitemid 28065253)
69. G. Comi, M. Filippi, F. Barkhof, L. Durelli, G. Edan, O. Fernandez, H. Hartung, P. Seeldrayers, P.S. Sorensen, M. Rovaris, V. Martinelli and O.R. Hommes: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357, 1576-1582 (2001). (Pubitemid 32488815)
70. L.D. Jacobs, R.W. Beck, J.H. Simon, R.P. Kinkel, C.M. Brownscheidle, T.J. Murray, N.A. Simonian, P.J. Slasor and A.W. Sandrock: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343, 898-904 (2000).
71. A. Compston and A. Coles: Multiple sclerosis. Lancet 359, 1221-1231 (2002). (Pubitemid 34304266)
72. K.B. Helle: The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects. Biol Rev Camb Philos Soc 79, 769-794 (2004). (Pubitemid 39577122)
73. A. Laslop, C. Weiss, D. Savaria, C. Eiter, S.A. Tooze, N.G. Seidah and H. Winkler: Proteolytic processing of chromogranin B and secretogranin II by prohormone convertases. J Neurochem 70, 374-383 (1998). (Pubitemid 28020865)
74. D.N. Irani, C. Anderson, R. Gundry, R. Cotter, S. Moore, D.A. Kerr, J.C. McArthur, N. Sacktor, C.A. Pardo, M. Jones, P.A. Calabresi and A. Nath: Cleavage of cystatin C in the cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 59, 237-247 (2006). (Pubitemid 43202476)
75. O. Carrette, P.R. Burkhard, S. Hughes, D.F. Hochstrasser and J.C. Sanchez: Truncated cystatin C in cerebrospiral fluid: Technical [corrected] artefact or biological process? Proteomics 5, 3060-3065 (2005). (Pubitemid 41176472)
76. P. Del Boccio, D. Pieragostino, A. Lugaresi, M. Di Ioia, B. Pavone, D. Travaglini, S. D'Aguanno, S. Bernardini, P. Sacchetta, G. Federici, C. Di Ilio, D. Gambi and A. Urbani: Cleavage of cystatin C is not associated with multiple sclerosis. Ann Neurol 62, 201-204 (2007). (Pubitemid 47546507)
77. I. Nakashima, M. Fujinoki, K. Fujihara, T. Kawamura, T. Nishimura, M. Nakamura and Y. Itoyama: Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis. Ann Neurol 62, 197-200 (2007). (Pubitemid 47546506)
78. H. Hermjakob: The HUPO Proteomics Standards Initiative - Overcoming the Fragmentation of Proteomics Data. Proteomics 6 Suppl 2, 34-38 (2006). (Pubitemid 44625766)
79. S. Orchard, H. Hermjakob and R. Apweiler: The proteomics standards initiative. Proteomics 3, 1374-1376 (2003). (Pubitemid 36929559)
80. M.Z. Man, G. Dyson, K. Johnson and B. Liao: Evaluating methods for classifying expression data. J Biopharm Stat 14, 1065-1084 (2004). (Pubitemid 39552545)
81. N. Andreasen, C. Hesse, P. Davidsson, L. Minthon, A. Wallin, B. Winblad, H. Vanderstichele, E. Vanmechelen and K. Blennow: Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and lateonset alzheimer disease and stability during the course of disease. Arch Neurol 56, 673-680 (1999). (Pubitemid 29266465)
82. M. Bibl, H. Esselmann, M. Otto, P. Lewczuk, L. Cepek, E. Ruther, J. Kornhuber and J. Wiltfang: Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 25, 2912-2918 (2004). (Pubitemid 39294839)
83. N.S. Schoonenboom, C. Mulder, H. Vanderstichele, E.J. Van Elk, A. Kok, G.J. Van Kamp, P. Scheltens and M.A. Blankenstein: Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 51, 189-195 (2005). (Pubitemid 40024030)
84. M.A. Korolainen, T.A. Nyman, P. Nyyssonen, E.S. Hartikainen and T. Pirttila: Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin Chem 53, 657-665 (2007). (Pubitemid 46580235)
85. J. Zhang, D.R. Goodlett, E.R. Peskind, J.F. Quinn, Y. Zhou, Q. Wang, C. Pan, E. Yi, J. Eng, R.H. Aebersold and T.J. Montine: Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid. Neurobiol Aging 26, 207-227 (2005). (Pubitemid 39610462)